Sort
30,917 grants matching “tumor microenvironment”
Molecular Pathology of Cancer
$766,965Michael R Emmert-Buck · Clinical Sciences · Z01 · FY2007 · CA
Enhance UCSC Xena: extend interactive visualization to ultra-large-scale multi-omics data and integrate with analysis resources
$766,920Jingchun Zhu · University Of California Santa Cruz · U24 · FY2021 · CA
Enhance UCSC Xena: extend interactive visualization to ultra-large-scale multi-omics data and integrate with analysis resources
$766,920Jingchun Zhu · University Of California Santa Cruz · U24 · FY2025 · CA
Co-evolution of the Reactive Microenvironment in Prostate Cancer Progression
$766,192David R Rowley · Baylor College Of Medicine · U54 · FY2009 · CA
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas
$766,065David M. Ashley · Duke University · R01 · FY2025 · CA
In Vivo Multiphoton Based Imaging of Complex Cancer Cell Behavior
$765,967Vladislav Verkhusha · Albert Einstein College Of Medicine · R01 · FY2012 · CA
Systems biology of intratumoral heterogeneity in glioblastoma
$765,787Nitin S Baliga · Institute For Systems Biology · R01 · FY2022 · CA
Molecular Biology of the Metastatic Phenotype
$765,528Patricia Schriver Steeg · Division Of Clinical Sciences - Nci · ZIA · FY2010 · CA
Towards a quantitative understanding of tumor evolution
$765,428Raul Rabadan · Columbia University Health Sciences · R35 · FY2023 · CA
Systems Modeling of Tumor Heterogeneity and Therapy Response in Colorectal Cancer
$765,244Fiona Ginty · General Electric Global Research Ctr · R01 · FY2018 · CA
ER stress and UPR in non-alcoholic steatohepatitis and hepatocellular carcinoma
$765,053Randal J. Kaufman · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2016 · CA
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies
$765,000Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2019 · CA
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies
$765,000Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2020 · CA
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies
$765,000Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2022 · CA
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies
$765,000Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2021 · CA
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies
$765,000Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2018 · CA
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer
$764,788Steven M. Dubinett · University Of California Los Angeles · U01 · FY2017 · CA
Mechanisms of pathogenesis in patient derived organoid models of prostate cancer
$764,220Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Novel SCD1 inhibitors for treatment of cancer
$763,181John A Copland · Modulation Therapeutics, Inc. · R42 · FY2018 · CA
Personalized Adoptive T-cell Therapy for AML
$762,763David E Avigan · Beth Israel Deaconess Medical Center · R01 · FY2021 · CA
Clinical Protocol and Data Management
$762,308Scott Michael Schuetze · University Of Michigan At Ann Arbor · P30 · FY2023 · CA
A turnkey research platform to accelerate clinical translation of targeted immune-modulation enhanced therapies
$762,081Ryan Gessner · Sonovol, Inc. · R44 · FY2022 · CA
Genomic dissection of tumor heterogeneity and progression
$761,986John Shern · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
New approach for immune modulation against T1D
$761,809Weston Daniel · Evoq Therapeutics, Inc. · R44 · FY2023 · DK
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
$761,749Andrew Sikora · University Of Tx Md Anderson Can Ctr · U01 · FY2020 · DE